Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

George Moore

Endocrinology, Diabetes & Metabolism Bothell, WA Medical Doctor

NPI 1588604110 CMS profile 26386

1909 214Th Street Se, Suite 211, Bothell, WA 98021

Open in the dashboard

General payments

$54,995

395 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, George Moore of Bothell, WA is reported in the CMS Open Payments database as having received $54,995 across 395 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $1,511 78
2020 General $2,449 72
2019 General $51,034 245

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Moore
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to George Moore were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year George Moore Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $51,034 $494 $123–$2,253 $163
2020 $2,449 $335 $85–$1,841 $114
2021 $1,511 $398 $88–$1,981 $132
2022 $0 $364 $88–$1,568 $149
2023 $0 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Amgen Inc. $40,085 83 payments
  2. Sanofi-Aventis U.S. LLC $10,770 38 payments
  3. Novo Nordisk Inc $590 41 payments
  4. Antares Pharma, Inc. $476 41 payments
  5. Amarin Pharma Inc. $408 22 payments
  6. Dexcom, Inc. $308 18 payments
  7. Lilly USA, LLC $266 22 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $245 30 payments
  9. AstraZeneca Pharmaceuticals LP $236 15 payments
  10. IBSA Pharma Inc. $182 11 payments
  11. Other $1,429 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $40,725 22 payments
  2. Travel and Lodging $7,224 25 payments
  3. Food and Beverage $6,985 345 payments
  4. Education $61 3 payments
Products named General payments · program years 2019–2021
  1. Prolia $26,988 45 payments
  2. EVENITY $12,871 32 payments
  3. SOLIQUA 100/33 $7,820 17 payments
  4. TOUJEO Diabetes $5,294 7 payments
  5. TOUJEO Endocrinology $734 1 payment
  6. Repatha $459 19 payments
  7. Ozempic $441 30 payments
  8. Vascepa $326 18 payments
  9. JARDIANCE $245 30 payments
  10. Otrexup $185 21 payments
  11. Other $3,426 204 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

395 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record